Esen Akpek, MD
Ophthalmology · Baltimore, MDNPI 1851356943
Payments from drug & device makers
Across 358 payments — averaging $3192.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$628K
- Ocular Therapeutix, Inc.$220K
- Regeneron$116K
- AbbVie$62K
- Bausch & Lomb Americas Inc.$23K
- Alcon$21K
- plus $73K from 14 others
Across 10 payments — averaging $793.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$7K
- KOWA Company, LTD.$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 232 | $627,754 |
| Ocular Therapeutix, Inc. | 11 | $219,760 |
| Regeneron | 52 | $116,395 |
| AbbVie(2 entities) | 6 | $61,881 |
| Bausch & Lomb Americas Inc. | 12 | $23,476 |
| Alcon | 5 | $21,052 |
| Dompe US, Inc. | 17 | $15,858 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15,000 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $9,210 |
| Dompe Farmaceutici S.p.a. | 5 | $7,507 |
| Janssen Scientific Affairs, LLC | 2 | $7,200 |
| Oyster Point Pharma, Inc. | 1 | $4,395 |
| Mallinckrodt Hospital Products Inc. | 2 | $3,700 |
| Janssen Global Services, LLC | 1 | $3,240 |
| Amgen | 1 | $2,500 |
| GSK | 1 | $1,625 |
| Harrow Eye, LLC | 1 | $1,400 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $780 |
| Thea Pharma Inc. | 3 | $206 |
| Tarsus Pharmaceuticals, Inc. | 2 | $135 |
How this compares
$1,143,073 in reported general payments places this provider in the 95th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Baltimore
- Daniel FinkelsteinBaltimore$6.9M
- Eric SuanBaltimore$6.9M
- Peter CampochiaroBaltimore$5.4M
- Neil BresslerBaltimore$3.6M
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- John ThompsonBaltimore$1.8M
- Peter McDonnellBaltimore$1.4M
- Earl CravenBaltimore$315K
- Akosua NtiBaltimore$315K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.